| Literature DB >> 34422962 |
Jeong-Moo Lee1, Kwangpyo Hong1, Eui Soo Han1, Sanggyun Suh1, Suyoung Hong1, Suk Kyun Hong1, YoungRok Choi1, Nam-Joon Yi1, Kwang-Woong Lee1, Kyung-Suk Suh1.
Abstract
BACKGROUND: Recipient hepatectomy during liver transplantation (LT) is one of the most challenging aspects of surgery due to the possibility of massive bleeding. This study aimed to compare and analyze the effectiveness between LigaSure and monopolar cautery in recipients.Entities:
Keywords: Liver transplantation (LT); hepatectomy postoperative hemorrhage; reoperation
Year: 2021 PMID: 34422962 PMCID: PMC8339826 DOI: 10.21037/atm-21-1318
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Clinical uses of LigaSure and monopolar cautery in the surgical field during liver transplantation. (A) Right liver mobilization using monopolar cautery. (B) Right liver mobilization using LigaSure (detachment from the diaphragm). (C) Blunt dissection around the right hepatic vein using LigaSure. (D) Ligation of the accessory left hepatic artery using LigaSure and a surgical tie.
Comparison of the postoperative outcomes between the LigaSure group and the monopolar cautery group
| Variable | LigaSure, N=69 | Monopolar cautery, N=69 | P value |
|---|---|---|---|
| Mean follow-up period (months ± SD) | 9.94±4.12 | 10.7±4.47 | 0.481 |
| Blood loss volume (mL; mean ± SD) | 5,486.5±9,024.6 | 4,754.3±6,819.5 | 0.592 |
| Amount of red blood cells transfused (packs; mean ± SD) | 11.01±13.75 | 10.21±12.52 | 0.447 |
| Operative time (mean ± SD) | |||
| Before PSM (69 versus 118) | 383.2±89.5 | 385.9±96.9 | 0.852 |
| After PSM | 383.2±89.5 | 384.8±88.7 | 0.914 |
| Skin incision to liver removal | 115.8±88.9 | 96.3±46.7 | 0.111 |
| Anastomosis establishment to skin closure | 82.8±44.7 | 68.8±29.2 | 0.033 |
| Overall complications | 23 (33.3%) | 37 (53.6%) | 0.017 |
| Biliary complication | 2 (2.90%) | 5 (7.25%) | 0.441 |
| Postoperative bleeding | 3 (4.35%) | 13 (18.8%) | 0.015 |
| Cardiovascular complication | 1 (1.45%) | 0 (0.0%) | 1.000 |
| HCC recurrence | 0 (0.00%) | 0 (0.00%) | 1.000 |
| Infectious complication | 1 (1.45%) | 9 (13.0%) | 0.017 |
| Rejection | 7 (10.14%) | 4 (5.79%) | 0.532 |
| Vascular complication | 5 (7.25%) | 4 (5.79%) | 0.730 |
| Wound complication | 5 (7.25%) | 2 (2.89%) | 0.441 |
| Major complications Clavien-Dindo classification > grade III | 10 (14.5%) | 22 (31.9%) | 0.016 |
| Re-operation due to bleeding | 3 (4.35%) | 13 (18.8%) | 0.015 |
| Hospital stay (days, mean ± SD) | 23.1±16.1 | 39.6±58.2 | 0.024 |
| In-hospital mortality | 0 (0.0%) | 0 (0.0%) | 1.000 |
HCC, hepatocellular carcinoma; PSM, propensity score matching; SD, standard deviation.
Preoperative characteristics before and after propensity score matching
| Variable | Before matching | After matching | |||||
|---|---|---|---|---|---|---|---|
| LigaSure (N=69) | Monopolar cautery (N=118) | P value | LigaSure (N=69) | Monopolar cautery (N=69) | P value | ||
| Age (years, mean ± SD) | 56.7±10.6 | 50.8±18.2 | 0.006 | 56.7±10.6 | 56.6±10.6 | 0.304 | |
| Gender (male/female) | 47/22 | 74/44 | 0.079 | 47/22 | 45/24 | 0.861 | |
| Height (cm, mean ± SD) | 187.8±18.2 | 168.4±6.4 | 0.011 | 187.8±18.2 | 165.1±7.73 | 0.246 | |
| Weight (kg, mean ± SD) | 66.9±13.4 | 66.6±13.9 | 0.456 | 66.9±13.4 | 64.4±11.6 | 0.245 | |
| BMI (kg/m2, mean ± SD) | 23.9±4.57 | 23.5±4.31 | 0.473 | 23.9±4.57 | 23.5±3.5 | 0.599 | |
| Diagnosis | 0.239 | ||||||
| HBV LC | 34 (49.3%) | 56 (47.5%) | 0.102 | 34 (49.3%) | 37 (53.6%) | ||
| HCV LC | 8 (11.6%) | 3 (2.5%) | 8 (11.6%) | 2 (2.9%) | |||
| Alcoholic LC | 18 (26.1%) | 18 (15.3%) | 18 (26.1%) | 12 (17.4%) | |||
| NBNC LC | 7 (25.9%) | 12 (10.2%) | 7 (25.9%) | 5 (7.2%) | |||
| Biliary Cirrhosis | 2 (7.4%) | 9 (7.6%) | 2 (7.4%) | 5 (7.2%) | |||
| AIH | 4 (14.8%) | 4 (3.4%) | 4 (14.8%) | 3 (4.3%) | |||
| BA | 3 (11.1%) | 5 (5.2%) | 3 (11.1%) | 0 (0.0%) | |||
| Budd-Chiari | 2 (7.4%) | 1 (0.8%) | 2 (7.4%) | 0 (0.0%) | |||
| Wilson | 2 (7.4%) | 2 (1.7%) | 2 (7.4%) | 2 (2.9%) | |||
| FHF | 1 (3.7%) | 2 (1.7%) | 1 (3.7%) | 1 (1.4%) | |||
| Others | 0 (0.0%) | 6 (5.1%) | 0 (0.0%) | 2 (2.9%) | |||
| HCC | 32 (46.4%) | 57 (48.3%) | 0.799 | 32 (46.4%) | 34 (49.3%) | 0.733 | |
| Non-HCC | 37 (53.6%) | 61 (51.7%) | 37 (53.6%) | 35 (50.7%) | |||
| LDLT/DDLT | 48/21 | 86/32 | 0.627 | 48/21 | 55/14 | 0.171 | |
| AFP (mean ± SD) | 715.9±3,956.1 | 2,943±18,298 | 0.237 | 715.9±3,956.1 | 1,383.8±4,689.3 | 0.382 | |
| PIVKA-II (mean ± SD) | 401.3±1,095.8 | 500.2±2,480 | 0.722 | 401.3±1,095.8 | 500.9±2,696.8 | 0.781 | |
| GRWR (mean ± SD) | 1.25±0.64 | 1.08±0.23 | 0.071 | 1.25±0.64 | 1.10±0.25 | 0.864 | |
| MELD score (mean ± SD) | 26.6±12.8 | 29.3±13.3 | 0.186 | 26.6±12.8 | 28.6±12.4 | 0.373 | |
| PLT count (×103/mL) | 79.7±52.0 | 88.8±57.1 | 0.279 | 79.7±52.0 | 78.4±48.7 | 0.878 | |
| PT INR (mean ± SD) | 1.69±0.89 | 1.58±0.78 | 0.424 | 1.69±0.89 | 1.62±0.87 | 0.681 | |
| Previous abdominal surgery | 17 (24.6%) | 27 (22.9%) | 0.858 | 17 (24.6%) | 11 (15.9%) | 0.204 | |
BMI, body-mass index; HBV LC, hepatitis B virus-related liver cirrhosis; HCV LC, hepatitis C virus-related liver cirrhosis; NBNC LC, non-B non C liver cirrhosis; AIH, autoimmune hepatitis; BA, biliary atresia; FHF, fulminant hepatic failure; HCC, hepatocellular carcinoma; LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation; AFP, alpha-feto protein; GRWR, graft recipient weight ratio; MELD, model for end-stage liver disease; PLT, platelet count; PT INR; prothrombin time international normalized ratio; PIVKA-II, protein induced by vitamin K absence II; PSM, propensity score matching; SD, standard deviation.